Crizotinib CAS 877399-52-5 Assay ≥99.0% API Factory High Quality
Shanghai Ruifu Chemical Co., Ltd. ndiye wopanga wamkulu wa Crizotinib (CAS: 877399-52-5) wokhala ndi mawonekedwe apamwamba.Ruifu Chemical imatha kubweretsa padziko lonse lapansi, mtengo wampikisano, ntchito zabwino kwambiri, zochepa komanso zochulukirapo zomwe zilipo.Gulani Crizotinib,Please contact: alvin@ruifuchem.com
| Dzina la Chemical | Crizotinib |
| Mawu ofanana ndi mawu | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3- [1- (2,6-Dichloro-3-Fluoro-phenyl)-ethoxy] -5-(1-Piperidin-4-yl-1H-pyrazol-4-yl) -pyridin-2-ylamine;(R) -3- [1- (2,6-Dichloro-3-Fluorophenyl) ethoxy]-5-(1-Piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylamine |
| Nambala ya CAS | 877399-52-5 |
| Stock Status | Mu Stock, Kupanga Kufikira Mazana a Kilogram |
| Molecular Formula | Chithunzi cha C21H22Cl2FN5O |
| Kulemera kwa Maselo | 450.34 |
| Melting Point | 192 ℃ |
| Kuchulukana | 1.47±0.10 g/cm3 |
| Kutentha Kosungirako | Kutentha kwa Chipinda |
| Chiyambi | Shanghai, China |
| Mtundu | Ruifu Chemical |
| Kanthu | Zofotokozera |
| Maonekedwe | Ufa Woyera mpaka Woyera |
| Chizindikiritso | Ndi IR, HPLC |
| Kumveka kwa Yankho | Gwirizanani ndi Standard |
| Kutaya pa Kuyanika | ≤1.00% |
| Zotsalira pa Ignition | ≤0.50% |
| Zowonongeka Zogwirizana nazo | (Wolemba HPLC) |
| Chidetso Chimodzi | ≤0.50% |
| Zonse Zonyansa | ≤1.00% |
| Zitsulo Zolemera | ≤20ppm |
| Kuyesa | ≥99.0% |
| Zosungunulira Zotsalira | Kumanani ndi Mafotokozedwe |
| Shelf Life | Miyezi 24 |
| Test Standard | Enterprise Standard |
Phukusi:Botolo, Aluminiyamu zojambulazo thumba, 25kg/Cardboard Drum, kapena malinga ndi zofunika kasitomala.
Mkhalidwe Wosungira:Sungani chidebecho chotsekedwa mwamphamvu ndikusunga pamalo ozizira, owuma (2~8 ℃) komanso molowera mpweya wabwino kutali ndi zinthu zomwe sizingagwirizane.Tetezani ku kuwala ndi chinyezi.
Manyamulidwe:Kutumiza kudziko lonse lapansi ndi ndege, ndi FedEx / DHL Express.Perekani mwamsanga ndi yodalirika yobereka.
Kufotokozera Zachitetezo 24/25 - Pewani kukhudzana ndi khungu ndi maso.
Ma ID a UN UN 3077 9 / PGIII
WGK Germany 3
HS kodi 2933990099
Kalasi Yowopsa IRRITANT
Crizotinib (CAS 877399-52-5), (Crizotinib, Xalkori R), ndi wamphamvu ndi kusankha ATP mpikisano yaying'ono molecule inhibitor wa ALK ndi c-Met.Mu Ogasiti 2011, United States FDA idavomereza Crizotinib kuti azichiza anaplastic lymphoma kinase (ALK) adakonzanso khansa ya m'mapapo yopanda maselo ang'onoang'ono (NSCLC).Crizotinib ndi wapawiri ATP competitive inhibitor wa tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50 = 8 nM) ndi ALK (cellular IC50 = 20 nM), zonse zomwe ndizofunikira kwambiri pamankhwala a khansa.Pamene crizotinib inayesedwa kuti ikhale yosankha motsutsana ndi kinase ina inapezeka kuti ili ndi enzyme IC50 mkati mwa 100-fold multiples ya c-MET kwa 13 ya 120 kinases yoyesedwa.Poyesa ma cell, crizotinib adapezeka kuti amaletsa RON (recepteur d'origine nantais) kinase yokhala ndi zenera la 10-fold selectivity pa c-MET.
Crizotinib (PF-02341066) Crizotinib ndi c-Met ndi ALK inhibitor yamphamvu, ma IC50 mu cell assay anali 11 nM ndi 24 nM, motero.Ilinso inhibitor yamphamvu ya ROS1 yokhala ndi mtengo wa Ki wochepera 0.025 nM.Crizotinib imatha kuyambitsa autophagy mumitundu yosiyanasiyana ya khansa ya m'mapapo poletsa njira ya STAT3.
Crizotinib ndi yamphamvu komanso yosankha yapawiri inhibitor ya mesenchymal-epithelial transition factor (c-MET) kinase ndi anaplastic lymphoma kinase (ALK).Crizotinib ndi antitumor wothandizira.Mu Ogasiti 2011, United States FDA idavomereza crizotinib kuti azichiza anaplastic lymphoma kinase (ALK) adakonzanso khansa ya m'mapapo yopanda maselo ang'onoang'ono (NSCLC).
Crizotinib (Xalkori(R), Pfizer), yovomerezedwa mu 2011, inali inhibitor yoyamba yovomerezeka yolunjika ku anaplastic lymphoma kinase (ALK).ROS protooncogene 1-encoded kinase (ROS1) ya tyrosine kinase insulin receptor class ndi MET proto-oncogene-encoded kinase of the hepatocyte growth factor receptor (HGFR) class are other kinase targeted by crizotinib.Pamene idavomerezedwa mu 2011, crizotinib inali yoyamba mankhwala olunjika makamaka odwala a NSCLC.Komabe, kukana kwa crizotinib nthawi zambiri kunkawoneka pafupifupi miyezi 8 mutatha kugwiritsa ntchito koyamba ndipo oposa theka la odwala omwe amathandizidwa ndi crizotinib anali ndi zotsatira za m'mimba.Mu 2016, Crizotinib idavomerezedwanso kuti ikhale ROS1-positive NSCLC ndi FDA.
Crizotinib (Xalkori) ndi oral receptor tyrosine kinase inhibitor yosonyezedwa pochiza odwala omwe ali ndi khansa yapamwamba kapena ya metastatic yopanda maselo ang'onoang'ono a m'mapapo (NSCLC).Zotsatira zoyipa zomwe zimagwiritsidwa ntchito ndi Xalkori zimaphatikizapo matenda am'mimba, nseru, kusanza, kupweteka m'mimba, kuchepa kwa njala, kusowa tulo, chizungulire, kutopa, kutsekula m'mimba, kudzimbidwa, totupa kapena kuyabwa, zizindikiro zozizira (mphuno, kuyetsemula, zilonda zapakhosi), dzanzi kapena kuyabwa, kapena kutupa m'manja kapena mapazi.
